Blood Coagulation Disorders, C.Surgical Procedure; Cardiac
Conditions
Brief summary
Cardiopulmonary bypass (CPB) is a unique clinical scenario that results in widespread activation of the hemostatic system. Conventional CPB interferes with normal hemostasis by diluting hemostatic cells and proteins, through reinfusion of shed blood, and through activation on the bypass circuit surface of multiple systems including platelets, the kallikrein-kinin system, and fibrinolysis . Besides, deleterious effects of cardiopulmonary bypass (CPB) are partly sequelae of blood-foreign surface reactions. The arterial filter is the part of the CPB circuit where blood cells are exposed to high mechanical stress and where cellular aggregates may fasten in large quantitiesiec.
Detailed description
This is a clinical and observational study. It is being performed in the surgical center and intensive care unit of the Heart Institute (InCor) from Faculty of Medicine, University of São Paulo (FMUSP), on patients undergoing cardiac surgery, who satisfy inclusion and exclusion criteria. In the preanesthetic visit, patient assessment of the criteria described in study methodology is verfied. During the surgery, a blood sample is taken to analyze hemostatic function in the begin of cardiopulmonary bypass, before arterial filter (pre-filter) and in the end of cardiopulmonary bypass, after arterial filter (post-filter). Other routine laboratory exams is being colected until first postoperative day, on the eletronic medical records. At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM. Ten arterial filter samples from pre-determined sites and sizes are sent to the clinical laboratory for evaluation of platelet and leukocyte gene expression in arterial filter. Patients will be followed until hospital discharge or 28 days after surgery, regarding allogeneic transfusion needs, reoperation and thromboembolic events.
Interventions
PROCEDUREAnalysis of arterial filters after CPB
At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
Sponsors
Instituto do Coracao
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Cardiac surgeries with extracorporeal circulation in patients older than 18 years * Written and signed informed consent * Preanesthetic assessment and preoperatory exams in accordance with study methodology
Exclusion criteria
* Active infection; * Previously coagulopathy; * Antiplatelet therapy use until 10 days before surgery (except acetylsalicylic acid and enoxaparin that may be used in prophylactic doses until 24h before surgery);
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Types and characteristics of materials entrapped in the arterial line filter of cardiopulmonary bypass | At the beginning and end of cardiopulmonary bypass | Analysis of the arterial filter from cardiopulmonay bypass circuit by scanning electron microscopy (SEM) |
| Platelet and leukocyte gene expression analysis of arterial line filters of cardiopulmonary bypass | At the beginning and end of cardiopulmonary bypass | Arterial filter samples from predetermined sites and sizes will be analyzed for evaluation of platelet and leukocyte gene expression in arterial filter. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between blood adhesion cells in arterial filter and coagulation tests | At the beginning and end of cardiopulmonary bypass | — |
| Comparison of standard coagulation test | At the beginning and end of cardiopulmonary bypass, Immediate postoperative; 24 hours and 48 hours after surgery | Analysis of coagulation profile will be assessed fibrinogen dosage (mg/dL), D-dimers (ng/mL), hemoglobin(g/dL), hematocrit (%), platelets count (mm³), prothrombin time (s), activated thromboplastin time (s), international normalized ratio. |
| Comparison of free oscillation rheometry profile | At the beginning and end of cardiopulmonary bypass | Analysis of HEPSCREEN (Reorox) COT1(s),COT2(s), Slope (Pa/min), GMAX (Pa), EAT (Pa), CLOT SR(%) |
Countries
Brazil
Contacts
Primary ContactFilomena Galas, Phd MD
Backup ContactChiara Gatto
Outcome results
None listed